News

Strategic Pivot to Pure-Play Biotech

POTOMAC, Maryland – March 18, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced it will demonstrate its Agentic Harmonization Assistant

POTOMAC, MARYLAND – February 26, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced the filing

POTOMAC, MARYLAND – February 24, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Ascendiant Capital Markets has issued an updated equity research report

– Practice integrated neurology network expands enrollment capacity –

POTOMAC, MARYLAND – February 17, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that the Canadian Intellectual Property Office (“CIPO”) has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company’s Phase 2 clinical stage program for agitation associated with Alzheimer’s disease.  With this allowance, patent No. 3,095,729, titled “Method and Composition

POTOMAC, MARYLAND – February 12, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET.   IGC Pharma’s management will

POTOMAC, Maryland – February 09, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia (“GNA”).   This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer’s population.  The GNA site is the latest addition to a

POTOMAC, MARYLAND – February 2, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease. 

POTOMAC, MARYLAND – January 22, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (“AI”) to develop innovative treatments for Alzheimer’s disease, today announced the addition of Integrative Clinical Trials,